The Blackstone Group, a major US private equity firm, has announced the acquisition of Takeda Consumer Healthcare Company (TCHC), a subsidiary of Takeda Pharmaceutical. Investment funds and other industries have been putting out feelers toward the pharmaceutical sector in recent…
HOME > REGULATORY
REGULATORY
- No New Concerns Found for Veklury’s Safety, Efficacy at This Point: MHLW Official
August 21, 2020
- Fujifilm’s Avigan COVID-19 Data Won’t Be Fully Ready until 1 Month from Now
August 21, 2020
- Japan Discussing Participation in COVAX Pact: Sr. Health Vice Minister
August 20, 2020
- Baqsimi’s NHI Tag Doubled on Foreign Price Adjustment, Payer Rep Questions Rule
August 20, 2020
- MHLW Panel to Vet Addition of 9-Valent HPV Vaccine into National Program
August 19, 2020
- Komeito Nudges Govt to Join COVAX Pact for Coronavirus Vaccine Procurement
August 19, 2020
- Entresto, Enerzair, 2 More HIF-PH Inhibitors OK'ed for Listing on August 26
August 19, 2020
- 22 Firms Get Approval for Lyrica Generics towards December Listing, Pfizer AG Included
August 18, 2020
- MHLW Grants Orphan Drug Status to Janssen’s Ibrutinib, 6 Other APIs
August 18, 2020
- Kaken’s Axillary Hyperhidrosis Drug, JT’s HIF-PH Inhibitor Up for MHLW Panel Review on Aug. 27
August 17, 2020
- MHLW Urges Trade Groups to Ensure Stable Supply of Povidone-Iodine Products
August 17, 2020
- AstraZeneca to Supply 120 Million Doses of COVID-19 Vaccine to Japan
August 11, 2020
- Japan to Grant Total of 90 Billion Yen to 6 Firms for COVID-19 Vaccine Production
August 11, 2020
- MHLW Warns of COVID-Tied Cyberattacks, Urges Companies to Boost Measures
August 7, 2020
- Tsutomu Iuchi to Lead MHLW's Medical Economics Division
August 6, 2020
- NIBIOHN, US Biotech to Develop COVID-19 Replicon RNA Vaccine; Japan PII Eyed Next Summer
August 5, 2020
- Japan Sketches Out Stable API Supply Measures, Set to Pick Key Drugs from 551 Candidates by March-End
August 4, 2020
- Tetsunari Kihira Appointed as Pharmaceutical Management Director
August 4, 2020
- Pfizer to Supply COVID-19 Vaccine Doses for 60 Million People in Japan
August 3, 2020
- PMDA Reviewing Safety Risks for Plaquenil, Relumina
August 3, 2020
ページ
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Despite the worldwide focus on inclusivity and diversity, it will take immediate action to counteract Japan’s growing gender gap. Study after study has proven that companies with more women in senior roles perform better financially, gaining a competitive edge from…